Multispecific Antibodies Cumulative Sales Have Already Surpassed USD 9 Billion By 2021 Says Kuick Research In Recent Reports On Bispecific & Trispecific Antibodies.
Multispecific Antibodies Cumulative Sales Have Already Surpassed USD 9 Billion By 2021 Says Kuick Research In Recent Reports On Bispecific & Trispecific Antibodies
In past years, advancement in the antibody engineering methodology has enabled the designing of diverse monoclonal antibody platforms ranging from nanobodies to multispecific antibodies. The multispecific antibodies are novel class of immunotherapy which has the ability to target multiple antigens at once and are therefore emerging as optimistic therapeutic antibody modalities in comparison to conventional monoclonal antibodies. Their growing interest in the pharmaceutical market is mainly due to the continuously growing number of mechanisms of actions they enable that are not accessible to monoclonal antibodies. Till date, various bispecific antibodies and trispecific antibodies have entered the clinical development and are indicated for the treatment of wide range of diseases including cancer, hemophilia, HIV, and other complex disorders.
Currently, only bispecific antibodies have gained approval in the global market including Blinatumomab (Blincyto), Emicizumab (Hemlibra), Amivantamab (Rybrevant), and Faricimab (Vabysmo). The entrance of bispecific antibody has shown high adoption rates owing to their ability to target the disease with high efficacy. Although trispecific antibodies have not gained entry into the market, the pipeline of trispecific antibodies is highly crowded. The major drugs in the clinical pipeline include GTB3550, GTB4550, HPN424, SAR443216, HPN217, and several others. GTB-3550 developed by GT Biopharma is one of the most promising Trike product candidates being initially developed for the treatment of acute myeloid leukemia, myelodysplastic syndrome, and other CD33+ hematologic cancers.
Global Bispecific Antibody Market Insight 2028 Report Highlights:
- Detailed Market Sales & Trends Insight
- Global and Regional Market Analysis
- Market Sales Insight 2020 Till 2028
- Approved Drug Sales Forecast Till 2028
- Approved Drug In Market: 4 Drugs
- Ongoing Clinical Trials Assessment by Status, Phase and Region
Download Report: https://www.kuickresearch.com/report-global-bispecific-antibodies-antibody-market-size-blincyto-hemlibra-rybrevant-sales
To further enhance the efficacy of multispecific antibodies, researchers are also evaluating the role of these drugs in combination with other regimens. For instance in April,22 collaboration and supply agreement was signed between SpringWork Therapeutics and Regeneron to evaluate nirogacestat, SpringWorks’ investigational gamma secretase inhibitor, in combination with Regeneron’s investigational bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3, REGN5458, in patients with relapsed or refractory multiple myeloma. Further, Harpoon Therapeutics entered into research collaboration and clinical supply agreement with Roche to evaluate the efficacy of HPN328 in combination with atezolizumab on solid tumors.
Global Trispecific Antibody Market Opportunity And Clinical Trials Insight 2028 Report Analysis and Data Highlights:
- Research Methodology
- Global Market Analysis
- Global Trispecific Antibody Market Opportunity Assessment: > USD 2 Billion
- US To Dominate Trispecific Antibodies Market: >70%
- Market and Drug Sales Insight 2024 Till 2028
- Future Market Assessment By Indication Till 2028
- Ongoing Clinical Trials Assessment by Status, Phase and Region
- Key Market Dynamics
- Competitor Landscape
Download Report: https://www.kuickresearch.com/report-trispecific-antibody-antibodies-market-clinical-trials-development-companies
Currently, there are more than 1000 ongoing clinical trials in global multispecific antibody market which is evaluating the role of novel drugs in the management of cancer. Apart from cancer, researchers are also evaluating the role of multispecific antibodies in the management of HIV, autoimmune disorders, and chronic diseases which is present at preclinical stage. By segment, cancer is expected to dominate the market attributing mainly to large number of products in clinical trials. Furthermore, the research will be mainly oriented towards cancer therapeutics attributing mainly to their high prevalence and unavailability of effectively curing drugs.
The global multispecific antibody market is highly competitive and the key players have adopted strategic alliances to maintain their position in the global market. For instance, Xencor has announced strategic research collaboration and commercialization agreement with The University of Texas MD Anderson Cancer Center to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer. The other key players in the market include Amgen, Gilead Science, Roche, Zai Lab, Beigene, Akeso, Innovent Biologics, and Novartis.
As per our report findings, the global multispecific antibody market is expected to surpass US$ 25 Billion Annual Sales by 2028. The major factors attributing to the growth of the multispecific antibody market are the rising adoption of antibody therapeutics over traditional therapy, emergence of biosimilars, rising prevalence of chronic diseases and lifestyle disorders, and rising demand for enhanced therapeutic antibodies. Furthermore, factors such as growing research collaborations, increasing number of research laboratories, and growing direct and indirect investments in research and development by pharmaceutical and biotechnology companies will also support the market’s growth in the coming years.
Contact:
Neeraj Chawla
Kuick Research
Research Head
+91-9810410366